156例低分子肝素钙治疗AECOPD的临床分析  

Clinical Analysis of Low Molecular Heparin Calcium Treating AECOPD in 156 Cases

作　　者：胡杰英[1] 邹少清[1] 

机构地区：[1]广东省农垦中心医院呼吸内科,广东湛江524002

出　　处：《临床医学工程》2012年第2期259-260,共2页Clinical Medicine & Engineering

摘　　要：目的观察低分子肝素钙对慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效。方法将156例病人根据病情分为轻度和重度两组,每组均随机分成治疗组和对照组,对照组给予常规治疗,治疗组在常规治疗基础上加低分子肝素钙治疗。结果重症患者使用低分子肝素钙治疗组各项指标均优于对照组,而两组轻症病人则无统计学差异。结论重度AECOPD患者常规综合基础治疗上加用低分子肝素钙能明显地改善患者症状和体征,缩短住院时间,降低死亡率,值得推广。Objective To explore the clinical effect of low molecular heparin calcium in the treatment of acute exacerbations ofchronic obstructive pulmonary disease （AECOPD）. Methods 156 cases were divided into light degree and heavy degree according to the condition; patients in each degree were divided into two groups： the control group with conventional treatment and the treatmentgroup with low molecular heparin calcium combined with conventional treatment. Results Every index of heavy degree in the treatment group was superior to the control group, while the index of light degree had no statistical difference in the two groups. Conclusion Low molecular heparin calcium combined with conventional treatment in patients with AECOPD can obviously improve the symptoms and signs, shorten the hospital stays and lower the mortality rate, which is worth popularizing.

关 键 词：低分子肝素钙:AECOPD 

分 类 号：R969.4[医药卫生—药理学]